fbpx

Cardiovascular disease in pregnancy

Updated : September 2, 2022





Background

Epidemiology

Anatomy

Pathophysiology

Etiology

Genetics

Prognostic Factors

Clinical History

Physical Examination

Age group

Associated comorbidity

Associated activity

Acuity of presentation

Differential Diagnoses

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

Medication

 

aspirin and omeprazole 

and prevention of cerebrovasular events
:

One tablet orally daily (available in aspirin 81 mg or 325 mg combinations)
Secondary cardiovascular prevention: 81 mg of aspirin has been accepted as the effective dosage for secondary cardiovascular prevention
Consider if current clinical practice recommendations require the 325-mg combination



Dose Adjustments

Dosage Modifications
Renal impairment
Mild-moderate: No dosage reduction is necessary.
Severe (GFR less than 10 mL/min): Avoid usage with aspirin (also see Cautions)
Hepatic impairment
Use with caution if there is any hepatic impairment
omeprazole systemic exposure is increased by hepatic impairment

 
 

Media Gallary

References

Cardiovascular disease in pregnancy

Updated : September 2, 2022




aspirin and omeprazole 

and prevention of cerebrovasular events
:

One tablet orally daily (available in aspirin 81 mg or 325 mg combinations)
Secondary cardiovascular prevention: 81 mg of aspirin has been accepted as the effective dosage for secondary cardiovascular prevention
Consider if current clinical practice recommendations require the 325-mg combination



Dose Adjustments

Dosage Modifications
Renal impairment
Mild-moderate: No dosage reduction is necessary.
Severe (GFR less than 10 mL/min): Avoid usage with aspirin (also see Cautions)
Hepatic impairment
Use with caution if there is any hepatic impairment
omeprazole systemic exposure is increased by hepatic impairment